1202 related articles for article (PubMed ID: 9024712)
41. [Comparison of adjuvant chemotherapy in breast carcinoma with a combination of cyclophosphamide, methotrexate, 5-fluorouracil (CMF) and AC (doxorubicin, cyclophosphamide). Initial results of a national cooperative study].
Pribylová O; Petruzelka L; Honová H; Fischer J; Bustová I; Siffnerová H; Kůta M; Miller V; Hacklová M; Machácek J; Kohoutek M; Vodvárka P; Kyselá T; Tajblová J; Suk J; Dorazilová V; Bauer J
Sb Lek; 1998; 99(1):25-31. PubMed ID: 9748796
[TBL] [Abstract][Full Text] [Related]
42. Adjuvant CMF for node-negative and estrogen receptor-negative breast cancer patients.
Zambetti M; Bonadonna G; Valagussa P; Daidone MG; Coradini D; Bignami P; Contesso G; Silvestrini R
J Natl Cancer Inst Monogr; 1992; (11):77-83. PubMed ID: 1627434
[TBL] [Abstract][Full Text] [Related]
43. Epirubicin versus mitoxantrone in combination chemotherapy for metastatic breast cancer.
Pavesi L; Preti P; Da Prada G; Pedrazzoli P; Poggi G; Robustelli della Cuna G
Anticancer Res; 1995; 15(2):495-501. PubMed ID: 7763029
[TBL] [Abstract][Full Text] [Related]
44. Treatment of metastatic breast cancer by navelbine, mitoxantrone and continuous infusion 5-fluorouracil (FMN regimen): results of a pilot study.
Azim HA
J Infus Chemother; 1996; 6(2):102-6. PubMed ID: 8809659
[TBL] [Abstract][Full Text] [Related]
45. Meningeal carcinomatosis in patients with breast carcinoma. Clinical features, prognostic factors, and results of a high-dose intrathecal methotrexate regimen.
Fizazi K; Asselain B; Vincent-Salomon A; Jouve M; Dieras V; Palangie T; Beuzeboc P; Dorval T; Pouillart P
Cancer; 1996 Apr; 77(7):1315-23. PubMed ID: 8608509
[TBL] [Abstract][Full Text] [Related]
46. Methotrexate, mitoxantrone, 5-fluorouracil and leucovorin in metastatic breast cancer patients.
Merlini L; Secondo V; Mammoliti S; Bellotti P; Castello C; Gallo L
Anticancer Res; 1994; 14(3B):1423-6. PubMed ID: 8067717
[TBL] [Abstract][Full Text] [Related]
47. Capecitabine/Cyclophosphamide/Methotrexate for patients with metastatic breast cancer: a dose-finding, feasibility, and efficacy study.
Mariani G; Petrelli F; Zambetti M; Moliterni A; Fasolo A; Marchiano A; Valagussa P; Gianni L
Clin Breast Cancer; 2006 Oct; 7(4):321-5. PubMed ID: 17092399
[TBL] [Abstract][Full Text] [Related]
48. A randomized comparison of cyclophosphamide-mitoxantrone-5-fluorouracil v cyclophosphamide-doxorubicin-5-fluorouracil in advanced breast cancer: preliminary observations.
Stewart DJ; Maroun JA; Hirte W; Perrault D; Stolbach L; Cripps C; Lefebvre B
Semin Oncol; 1984 Sep; 11(3 Suppl 1):23-7. PubMed ID: 6385261
[TBL] [Abstract][Full Text] [Related]
49. Circadian rhythm-modulated (CRM) chemotherapy of metastatic breast cancer with mitoxantrone, 5-fluorouracil, and folinic acid: preliminary results of a phase I trial.
Deprés-Brummer P; Berthault-Cvitkovic F; Lĕvi F; Brienza S; Vannetzel JM; Jasmin C; Misset JL
J Infus Chemother; 1995; 5(3 Suppl 1):144-7. PubMed ID: 8528975
[TBL] [Abstract][Full Text] [Related]
50. Cyclophosphamide/mitoxantrone/melphalan (CMA) regimen prior to autologous bone marrow transplantation (ABMT) in metastatic breast cancer.
Gisselbrecht C; Extra JM; Lotz JP; Devaux Y; Janvier M; Peny AM; Guillevin L; Bremond D; Delain M; Herbrecht R; Lepage E; Maraninchi D
Bone Marrow Transplant; 1996 Nov; 18(5):857-63. PubMed ID: 8932837
[TBL] [Abstract][Full Text] [Related]
51. [Systemic chemotherapy of mammary carcinoma: plasma and tissue concentrations of 5-fluorouracil and adriamycin, and result of CAF and CMF therapy of breast cancer].
Murayama Y; Nagashima M
Gan To Kagaku Ryoho; 1984 Mar; 11(3):415-9. PubMed ID: 6546655
[TBL] [Abstract][Full Text] [Related]
52. Anticipatory vomiting in women receiving cyclophosphamide, methotrexate, and 5-FU (CMF) adjuvant chemotherapy for breast carcinoma.
Wilcox PM; Fetting JH; Nettesheim KM; Abeloff MD
Cancer Treat Rep; 1982 Aug; 66(8):1601-4. PubMed ID: 7049385
[TBL] [Abstract][Full Text] [Related]
53. Dose-intensive epirubicin-based chemotherapy is superior to an intensive intravenous cyclophosphamide, methotrexate, and fluorouracil regimen in metastatic breast cancer: a randomized multinational study.
Ackland SP; Anton A; Breitbach GP; Colajori E; Tursi JM; Delfino C; Efremidis A; Ezzat A; Fittipaldo A; Kolaric K; Lopez M; Viaro D;
J Clin Oncol; 2001 Feb; 19(4):943-53. PubMed ID: 11181656
[TBL] [Abstract][Full Text] [Related]
54. The use of mitoxantrone, 5-fluorouracil and high-dose leucovorin in the treatment of advanced breast cancer.
Hainsworth JD
Ann Oncol; 1993; 4 Suppl 2():37-40. PubMed ID: 7688982
[TBL] [Abstract][Full Text] [Related]
55. A phase II trial of cyclophosphamide, methotrexate, 5-fluorouracil, and prednisolone rapidly alternating with doxorubicin and vincristine (CMFP/AV) in advanced breast cancer.
Rischin D; Bishop JF; Olver IN; Laidlaw CR; Zimet A; Jeal P; Dipell JF
Am J Clin Oncol; 1992 Oct; 15(5):392-4. PubMed ID: 1524039
[TBL] [Abstract][Full Text] [Related]
56. Randomized trial comparing two different modalities of administration of the same cytotoxic drugs in metastatic breast cancer.
Pierga JY; Jouve M; Asselain B; Beuzeboc P; Dorval T; Palangie T; Dieras V; Garcia-Giralt E; Scholl S; Pouillart P
J Infus Chemother; 1995; 5(4):197-200. PubMed ID: 8934727
[TBL] [Abstract][Full Text] [Related]
57. [Combination of 5-FU, high dose methotrexate, epirubicin and cisplatin (FEMTX-P protocol) in non surgical or locally recurrent metastatic gastric cancers].
Conroy T; Wils J; Paillot B; Wagener DJ; Burghouts JT; Fickers MM; de Graeff A; Lalisang FM
Bull Cancer; 1993 Mar; 80(3):255-60. PubMed ID: 8173178
[TBL] [Abstract][Full Text] [Related]
58. Neoadjuvant chemotherapy with cyclophosphamide, mitoxantrone, and 5-fluorouracil in locally advanced breast cancer.
Erol K; Baltali E; Altundag K; Guler N; Ozisik Y; Onat DA; Sayek I; Cengiz M; Atahan L; Tekuzman G
Onkologie; 2005 Feb; 28(2):81-5. PubMed ID: 15662111
[TBL] [Abstract][Full Text] [Related]
59. Randomized, controlled, multicenter phase III trial of standard-dose fluorouracil-epirubicin-cyclophosphamide (FEC), compared with time-intensive FEC (FEC-G) and mitoxantrone-methotrexate-mitomycin C (MMM-G) in metastatic breast carcinoma.
Capotorto AM; Pavesi L; Pedrazzoli P; Da Prada GA; Zamagni C; Massidda B; Farris A; Martoni A; Lelli G; Robustelli della Cuna G
J Chemother; 2003 Apr; 15(2):184-91. PubMed ID: 12797397
[TBL] [Abstract][Full Text] [Related]
60. Comparison of costs for infusion versus bolus chemotherapy administration--Part two. Use of charges versus reimbursement for cost basis.
Lokich JJ; Moore CL; Anderson NR
Cancer; 1996 Jul; 78(2):300-3. PubMed ID: 8674007
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
